TuHURA Biosciences, Inc. · NASDAQ:HURA
TuHURA Biosciences — Investor Presentation (May 2026)
23 slides from TuHURA Biosciences's investor presentation, May 2026
Slide 1: Overcoming Resistance to Cancer Immunotherapy
Overcoming Resistance to Cancer Immunotherapy May 2026 tuhurabio.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” under the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, and TuHURA’s actual results may differ from its expectations, estimates and projections expressed in its forwa
Slide 3: We are a Phase 3 immuno-oncology company
We are a Phase 3 immuno- oncology company developing three distinct novel technologies and therapeutics to overcome primary and acquired resistance to cancer immunotherapies 3
Slide 4: Investment Highlights
Investment Highlights Overcoming resistance to cancer immunotherapies IFx-2.0 in a Ph3 accelerated approval study in 1st Line Merkel Cell Carcinoma • Top-line data expected 2H 2027 • Confirmatory trial not expected to be required • Special Protocol Assessment (SPA) Agreement with the FDA VISTA inhib
Slide 5: $50 Million Credit Facility & Royalty Transaction
$50 Million Credit Facility & Royalty Transaction Non-equity $50mm facility to fund all upcoming program milestones through IFx-2.0 Phase 3 Results • Provides Optionality: • Capital market independence and into 2028 • TuHURA controls amounts of monthly draws if any and retains ability to access capi
Slide 6: Diversified Immuno-Oncology Pipeline
Diversified Immuno-Oncology Pipeline PROGRAM DRUG CANDIDATE INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Upcoming Milestone 1st Line Merkel Cell Cancer 2H 2027: Phase 3 Keytruda® +/- IFx-2.0 or Expected Topline Results IFx-2.0 placebo1 Innate Immune Innate Immune Agonists Agonist Primary Checkpoin
Slide 7: IFx Technology
IFx Technology Innate Immune Agonists Designed to Overcome Primary Resistance to Checkpoint Inhibitors
Slide 8: IFx-2.0: Mechanism of Action
IFx-2.0: Mechanism of Action Making a Tumor Look Like a Bacterium Initiation of an Innate Immune Response Activation of Tumor Specific T Cells Allows CPI to work where they previously failed 1Intra-tumoral injection of 3 4 5 pDNA results in expression bacterial protein on surface of tumor – making t
Slide 9: Advanced Metastatic Merkel Cell Carcinoma: 50% Don't Respond to 1st Line Keytruda
Advanced Metastatic Merkel Cell Carcinoma 50% of Patients Don’t Respond to 1st Line Keytruda® Keytruda® (pembrolizumab) is the 1st line standard of care for Probability of disease progression at advanced metastatic MCC two years is 26%, 57% and 100% for those with CR, PR and SD, respectively 20% 36%
Slide 10: Phase 1b Study in Advanced Skin Cancer
Phase 1b Study in Advanced Skin Cancer (Merkel Cell and Cutaneous Squamous Cell Carcinoma) Safety Evaluable (n=21) TRAEs Dose and Schedule Enrolled n=23 Selected: (13 MCC, 10 SCC) Grade 1 35% (8) 1-3 lesions, Weekly x 3 Grade 3 4% (1) Response Evaluable Best Overall Median Duration of MCC (n=9) Resp
Slide 11: IFx-2.0 Phase 1b Advanced, Metastatic Merkel Cell Carcinoma
IFx-2.0 Phase 1b Advanced, Metastatic Merkel Cell Carcinoma Encouraging durable responses in CPI resistant MCC 2 PD CR 23 4 pCR PD 23 3 PR PD 33 5 PD PR 19 Patient 11 PD PR 11 15 PD PR 6 7 PD NR 13 PD NR 14 PD NR 0 5 10 15 20 25 30 35 40 IFx-2.0 Administration Months Response to CPI Pre IFx-2.0 Resp
Slide 12: IFx-2.0 Phase 1b Trial in Advanced Metastatic Merkel Cell Carcinoma
IFx-2.0 Phase 1b Trial in Advanced Metastatic Merkel Cell Carcinoma Progressed through 3 months of Post IFx-2.0 Keytruda® Progressed through 2 months of Post IFx-2.0 rechallenged with Keytruda® (pembrolizumab). (pembrolizumab) rechallenge. Keytruda®. Large bulky abdominal checkpoint inhibitor, Baven
Slide 13: Single Phase 3 Accelerated Approval Trial
Single Phase 3 Accelerated Approval Trial Designed with OCE1 – Utilized Project Front Runner Initiative 1st line CPI naïve, advanced/metastatic MCC 1:1 Randomization, Placebo, Injection Controlled Trial Primary Endpoint Overall Response Rate (ORR) Key Secondary Endpoint Progression Free Survival (PF
Slide 14: TBS-2025 VISTA Inhibiting mAb
TBS-2025 VISTA Inhibiting mAb
Slide 15: Targeting VISTA: a new checkpoint target in AML, MDS
Broad Potential in Blood Related Targeting VISTA: a new Malignancies checkpoint target in AML, MDS VISTA is a novel negative checkpoint highly expressed on: Strategic Focus and Technology Synergies Leukemic blasts Myeloid Derived Suppressor Cells (MDSCs) Quiescent T Cells – VISTA maintains resting S
Slide 16: TBS2025: Scientific Rational for VISTA in AML
TBS2025: Scientific Rational for VISTA in AML Strong Scientific Rational for VISTA in AML • Only checkpoint highly expressed in AML • Expression driven by most common mutations in AML (NPM1, FLT-3) • Presence on leukemic blast in patients correlates with poor survival • Suppression of T cell activit
Slide 17: TBS2025: A novel VISTA inhibiting antibody
TBS2025: A novel VISTA inhibiting antibody FDA guidance: r/r AML with no effective or approved therapies • Phase 1b mutNPM1 r/r AML: Abbreviated dose escalation for PK and RPD2 • 75% of patients don't respond to or relapse following menin inhibitors • Represents an unmet medical need patient populat
Slide 18: Bi-Specific, Bi-Functional Antibody Drug Conjugates ADCs
Bi-Specific, Bi-Functional Antibody Drug Conjugates ADCs First in class immune modulating ADCs targeting MDSCs and Tregs
Slide 19: First-in-Class Immune Modulating Bi-functional, Bi-specific ADC
We Are Developing a First-in-Class Immune Modulating Bi-functional, Bi- specific Antibody Drug Conjugates (ADC) Targeting MDSCs, Tregs to overcome acquired resistance to cancer immunotherapies Anti-VISTA mAb • Non tumor targeting, non internalizing, non cytotoxic or cell cycle targeting payloads • B
Slide 20: Delta Opioid Receptor controls immune suppressing genes in MDSCs, Tregs
Delta Opioid Receptor controls the expression of multiple immune suppressing genes in MDSCs, Tregs • MDSCs • Produce a cascade of immune suppressing factors (iNOS, COX2, IDO) • Attract other immune suppressing cells Tregs • Blocking DOR inhibits immune suppressing genes • MDSCs (iNOS, COX2, ROS) • T
Slide 21: Upcoming Milestone Targets
Upcoming Milestone Targets 2026 2027 1H 2026 2H 2026 1H 2027 2H 2027 Complete Enrollment in IFx-2.0 Ph3 IFx-2.0 study Orphan Drug Innate Immune Designation MCC Agonist Top Line Results Ph3 IFx-2.0 study TBS-2025 Orphan Drug Designation AML Planned FDA IND Mtg re VISTA Inhibiting development plan Ph
Slide 22: Investment Highlights
Investment Highlights Overcoming resistance to cancer immunotherapies IFx-2.0 in a Ph3 accelerated approval study in 1st Line Merkel Cell Carcinoma • Top-line data expected 2H 2027 • Confirmatory trial not expected to be required • Special Protocol Assessment (SPA) Agreement with the FDA VISTA inhib
Slide 23: Overcoming Resistance to Cancer Immunotherapy
Overcoming Resistance to Cancer Immunotherapy tuhurabio.com
TuHURA Biosciences — Investor Presentation (May 2026) on 6ix